These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
308 related articles for article (PubMed ID: 28956184)
1. Reliable diagnosis of IDH-mutant glioblastoma by 2-hydroxyglutarate detection: a study by 3-T magnetic resonance spectroscopy. Natsumeda M; Motohashi K; Igarashi H; Nozawa T; Abe H; Tsukamoto Y; Ogura R; Okada M; Kobayashi T; Aoki H; Takahashi H; Kakita A; Okamoto K; Nakada T; Fujii Y Neurosurg Rev; 2018 Apr; 41(2):641-647. PubMed ID: 28956184 [TBL] [Abstract][Full Text] [Related]
2. Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy. Natsumeda M; Igarashi H; Nomura T; Ogura R; Tsukamoto Y; Kobayashi T; Aoki H; Okamoto K; Kakita A; Takahashi H; Nakada T; Fujii Y Acta Neuropathol Commun; 2014 Nov; 2():158. PubMed ID: 25376594 [TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma. Nagashima H; Tanaka K; Sasayama T; Irino Y; Sato N; Takeuchi Y; Kyotani K; Mukasa A; Mizukawa K; Sakata J; Yamamoto Y; Hosoda K; Itoh T; Sasaki R; Kohmura E Neuro Oncol; 2016 Nov; 18(11):1559-1568. PubMed ID: 27154922 [TBL] [Abstract][Full Text] [Related]
4. Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting. Tietze A; Choi C; Mickey B; Maher EA; Parm Ulhøi B; Sangill R; Lassen-Ramshad Y; Lukacova S; Østergaard L; von Oettingen G J Neurosurg; 2018 Feb; 128(2):391-398. PubMed ID: 28298040 [TBL] [Abstract][Full Text] [Related]
5. Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients. Jafari-Khouzani K; Loebel F; Bogner W; Rapalino O; Gonzalez GR; Gerstner E; Chi AS; Batchelor TT; Rosen BR; Unkelbach J; Shih HA; Cahill DP; Andronesi OC Neuro Oncol; 2016 Nov; 18(11):1569-1578. PubMed ID: 27382115 [TBL] [Abstract][Full Text] [Related]
6. Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma. Choi C; Raisanen JM; Ganji SK; Zhang S; McNeil SS; An Z; Madan A; Hatanpaa KJ; Vemireddy V; Sheppard CA; Oliver D; Hulsey KM; Tiwari V; Mashimo T; Battiste J; Barnett S; Madden CJ; Patel TR; Pan E; Malloy CR; Mickey BE; Bachoo RM; Maher EA J Clin Oncol; 2016 Nov; 34(33):4030-4039. PubMed ID: 28248126 [TBL] [Abstract][Full Text] [Related]
7. 2-Hydroxyglutarate magnetic resonance spectroscopy in adult brainstem glioma. Iwahashi H; Nagashima H; Tanaka K; Uno T; Hashiguchi M; Maeyama M; Somiya Y; Komatsu M; Hirose T; Itoh T; Sasaki R; Sasayama T J Neurosurg; 2023 Aug; 139(2):355-362. PubMed ID: 36708540 [TBL] [Abstract][Full Text] [Related]
8. Comparative Value of 2-Hydroxyglutarate-to-Lipid and Lactate Ratio versus 2-Hydroxyglutarate Concentration on MR Spectroscopic Images for Predicting Isocitrate Dehydrogenase Mutation Status in Gliomas. Suh CH; Kim HS; Park JE; Jung SC; Choi CG; Woo DC; Lee HB; Kim SJ Radiol Imaging Cancer; 2020 Jul; 2(4):e190083. PubMed ID: 33778723 [TBL] [Abstract][Full Text] [Related]
9. Intraoperative assessment of isocitrate dehydrogenase mutation status in human gliomas using desorption electrospray ionization-mass spectrometry. Alfaro CM; Pirro V; Keating MF; Hattab EM; Cooks RG; Cohen-Gadol AA J Neurosurg; 2020 Jan; 132(1):180-187. PubMed ID: 30611146 [TBL] [Abstract][Full Text] [Related]
10. Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomas. Zhou M; Zhou Y; Liao H; Rowland BC; Kong X; Arvold ND; Reardon DA; Wen PY; Lin AP; Huang RY Neuro Oncol; 2018 Aug; 20(9):1262-1271. PubMed ID: 29438510 [TBL] [Abstract][Full Text] [Related]
11. The diagnostic efficiency of integration of 2HG MRS and IVIM versus individual parameters for predicting IDH mutation status in gliomas in clinical scenarios: A retrospective study. Yu M; Ge Y; Wang Z; Zhang Y; Hou X; Chen H; Chen X; Ji N; Li X; Shen H J Neurooncol; 2024 Apr; 167(2):305-313. PubMed ID: 38424338 [TBL] [Abstract][Full Text] [Related]
12. Spectroscopic imaging of D-2-hydroxyglutarate and other metabolites in pre-surgical patients with IDH-mutant lower-grade gliomas. Autry AW; Lafontaine M; Jalbert L; Phillips E; Phillips JJ; Villanueva-Meyer J; Berger MS; Chang SM; Li Y J Neurooncol; 2022 Aug; 159(1):43-52. PubMed ID: 35672531 [TBL] [Abstract][Full Text] [Related]
13. Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate. Andronesi OC; Loebel F; Bogner W; Marjańska M; Vander Heiden MG; Iafrate AJ; Dietrich J; Batchelor TT; Gerstner ER; Kaelin WG; Chi AS; Rosen BR; Cahill DP Clin Cancer Res; 2016 Apr; 22(7):1632-41. PubMed ID: 26534967 [TBL] [Abstract][Full Text] [Related]
14. Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. de la Fuente MI; Young RJ; Rubel J; Rosenblum M; Tisnado J; Briggs S; Arevalo-Perez J; Cross JR; Campos C; Straley K; Zhu D; Dong C; Thomas A; Omuro AA; Nolan CP; Pentsova E; Kaley TJ; Oh JH; Noeske R; Maher E; Choi C; Gutin PH; Holodny AI; Yen K; DeAngelis LM; Mellinghoff IK; Thakur SB Neuro Oncol; 2016 Feb; 18(2):283-90. PubMed ID: 26691210 [TBL] [Abstract][Full Text] [Related]
15. In-Vivo Proton Magnetic Resonance Spectroscopy of 2-Hydroxyglutarate in Isocitrate Dehydrogenase-Mutated Gliomas: A Technical Review for Neuroradiologists. Kim H; Kim S; Lee HH; Heo H Korean J Radiol; 2016; 17(5):620-32. PubMed ID: 27587950 [TBL] [Abstract][Full Text] [Related]
16. IDH1 p.R132H ctDNA and D-2-hydroxyglutarate as CSF biomarkers in patients with IDH-mutant gliomas. Fujita Y; Nunez-Rubiano L; Dono A; Bellman A; Shah M; Rodriguez JC; Putluri V; Kamal AHM; Putluri N; Riascos RF; Zhu JJ; Esquenazi Y; Ballester LY J Neurooncol; 2022 Sep; 159(2):261-270. PubMed ID: 35816267 [TBL] [Abstract][Full Text] [Related]
17. 2-Hydroxyglutarate MR spectroscopy for prediction of isocitrate dehydrogenase mutant glioma: a systemic review and meta-analysis using individual patient data. Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ Neuro Oncol; 2018 Nov; 20(12):1573-1583. PubMed ID: 30020513 [TBL] [Abstract][Full Text] [Related]
18. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Andronesi OC; Kim GS; Gerstner E; Batchelor T; Tzika AA; Fantin VR; Vander Heiden MG; Sorensen AG Sci Transl Med; 2012 Jan; 4(116):116ra4. PubMed ID: 22238332 [TBL] [Abstract][Full Text] [Related]
19. In vivo 2-hydroxyglutarate-proton magnetic resonance spectroscopy (3 T, PRESS technique) in treatment-naïve suspect lower-grade gliomas: feasibility and accuracy in a clinical setting. Cuccarini V; Antelmi L; Pollo B; Paterra R; Calatozzolo C; Nigri A; DiMeco F; Eoli M; Finocchiaro G; Brenna G; Tramacere I; Bruzzone MG; Anghileri E Neurol Sci; 2020 Feb; 41(2):347-355. PubMed ID: 31650436 [TBL] [Abstract][Full Text] [Related]
20. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Choi C; Ganji SK; DeBerardinis RJ; Hatanpaa KJ; Rakheja D; Kovacs Z; Yang XL; Mashimo T; Raisanen JM; Marin-Valencia I; Pascual JM; Madden CJ; Mickey BE; Malloy CR; Bachoo RM; Maher EA Nat Med; 2012 Jan; 18(4):624-9. PubMed ID: 22281806 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]